文献速递免疫规划妇幼与学校卫生

铝佐剂呼吸道合胞病毒F颗粒疫苗制剂在健康育龄女性中的2期随机、观察者盲、安慰剂对照、剂量递增试验

A Phase 2 randomized, observer-blind, placebo-controlled, dose-ranging trial of aluminum-adjuvanted respiratory syncytial virus F particle vaccine formulations in healthy women of childbearing age.
PubMed 文献 · Vaccine · 2017-06-01

该2期随机观察者盲安慰剂对照剂量递增试验在健康18-35岁女性中比较含60μg或120μg RSV F蛋白与0.2、0.4或0.8mg铝的疫苗及安慰剂在第0天和第28天肌内接种的免疫原性与安全性,所有制剂耐受良好且无治疗相关严重不良事件,120μg RSV F加0.4mg铝可最快速产生最强抗体应答。

要点

  • 所有疫苗制剂耐受良好,无治疗相关严重不良事件。
  • 抗F IgG和PCA应答在两次剂量后均升高且相关,MN仅首剂后显著升高后平台。
  • 120μg RSV F加0.4mg铝应答最快最强,两剂60μg加0.8mg铝91天持久性约优25%。

核心结论

  • RSV F纳米颗粒疫苗制剂耐受良好且具免疫原性。
  • 孕晚期免疫便利性与快速应答的最佳组合为120μg RSV F加0.4mg铝,14天达峰值免疫应答且91天持久性足以允许IgG被动转移至胎儿。

研究设计与样本

  • 2期随机、观察者盲、安慰剂对照、剂量递增试验。
  • 健康18-35岁女性肌内接种安慰剂或含60μg或120μg RSV F蛋白与0.2、0.4或0.8mg铝的疫苗,第0天和第28天各一剂。
  • 免疫原性从第0天至第91天评估,基于ELISA测抗F IgG和帕利珠单抗竞争抗体(PCA),微量中和试验测RSV A和B中和抗体。

主要发现

  • 所有制剂耐受良好,无治疗相关严重不良事件。
  • 抗F IgG和PCA应答相关,两次剂量后均升高;MN仅首剂后显著升高,随后平台。
  • 120μg RSV F加0.4mg铝后抗体应答最及时且最强。
  • 两剂60μg RSV F加0.8mg铝后91天持久性适度(约25%)更优。
  • Western blot分析显示,第0天至第90天期间,活性疫苗受试者RSV感染总体减少52%(p=0.009)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Respiratory syncytial virus (RSV) causes significant morbidity and mortality in infants. We are developing an RSV fusion (F) protein nanoparticle vaccine for immunization of third trimester pregnant women to passively protect infants through transfer of RSV-specific maternal antibodies. The present trial was performed to assess the immunogenicity and safety of several formulations of RSV F vaccine in 1-dose or 2-dose schedules. METHODS: Placebo, or vaccine with 60μg or 120μg RSV F protein and 0.2, 0.4, or 0.8mg aluminum, were administered intramuscularly on Days 0 and 28 to healthy women 18-35years old. Immunogenicity was assessed from Days 0 through 91 based on anti-F IgG and palivizumab-competitive antibody (PCA) by ELISA, and RSV A and B neutralizing antibodies by microneutralization (MN) assay. Solicited adverse events were collected through Day 7 and unsolicited adverse events through Day 91. RESULTS: All formulations were well-tolerated, with no treatment-related serious adverse events. Anti-F IgG and PCA responses were correlated and increased after both doses, while MN increased significantly only after the first dose, then plateaued. The timeliest and most robust antibody responses followed one dose of 120μg RSV F protein and 0.4mg aluminum, but persistence through 91days was modestly (∼25%) superior following two doses of 60μg RSV F protein and 0.8mg aluminum. Western blot analysis showed RSV infections in active vaccinees were reduced by 52% overall (p=0.009 overall) over the Day 0 through 90 period. CONCLUSIONS: RSV F nanoparticle vaccine formulations were well tolerated and immunogenic. The optimal combination of convenience and rapid response for immunization in the third trimester occurred with 120μg RSV F and 0.4mg aluminum, which achieved peak immune responses in 14days and sufficient persistence through 91days to allow for passive transfer of IgG antibodies to the fetus. NCT01960686.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. August A, Glenn GM, Kpamegan E, et al. A Phase 2 randomized, observer-blind, placebo-controlled, dose-ranging trial of aluminum-adjuvanted respiratory syncytial virus F particle vaccine formulations in healthy women of childbearing age. Vaccine. 2017. PMID: 28579233. doi:10.1016/j.vaccine.2017.05.045

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。